Maze Therapeutics price target raised to $34 from $28 at Leerink

Leerink analyst Joseph Schwartz raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $28 and keeps an Outperform rating on the shares. First-in-human Phase 1 data with MZE782 exceeded the firm’s expectations and support the potential for a best-in-class profile, the analyst tells investors in a research note. The firm added that it remains positive on the stock ahead of the APOL1 data in early 2026, and that its price target has risen after the firm raised its probability-of-success estimate for MZE782.